Bionano genomics news.
CONTACTS. SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.
UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the …In a single enzymatic reaction, the Bionano Direct Label and Stain (DLS) workflow recognizes a 6 bp sequence motif occurring approximately 14-17 times per 100 kbp in the human genome and transfers a fluorescent label to it via covalent modification. This labeling step results in a uniquely identifiable sequence-specific pattern of labels to be used for …Mar 9, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the …
An Accounting Trick Not to Neglect. Shareholders of Bionano Genomics have been diluted in the past year, with total shares outstanding growing by 6.4%.. This is the base news for valuation ...The average price point forecasted by analysts for Bionano Genomics Inc (BNGO) is $12.33, which is $10.7 above the current market price. The public float for BNGO is 38.09M, and currently, short sellers hold a 17.35% ratio of that float. The average trading volume of BNGO on November 27, 2023 was 888.80K shares. Top 5 EV Tech Stocks to Buy for ...Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
Bionano Genomics sees Q3 net loss widen 53% but beats on the top line SA News Thu, Nov. 03, 2022 Bionano Genomics net loss of $31.81M, revenue of …
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.. Conference Call & Webcast DetailsFollowing the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...Mar 31, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr ® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the release of Bionano Solve™ version 3.7 and Bionano Access™ version 1.7 as available data solution …
Good news: those days are over. VIA software radically simplifies your sample-to-report workflow and empowers you to deliver more clinically relevant answers from across technologies faster. VIA brings various data types into one view and automates variant calling, interpretation and annotation, so you can reduce turnaround times and optimize …
Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theAbout Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCONTACTS. SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that its Chinese original equipment manufacturing (OEM) partner, Beijing Genome Precision Technology (BGPT), a comprehensive molecular diagnostics company, has obtained reagent class I registrations from China's National Medical Products Administration ...
Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025... SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million …Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.NEW YORK (GenomeWeb) – Bionano Genomics has priced its initial public offering of 3.36 million units at $6.125 per unit, bringing in total gross proceeds of $20.58 million, and has started trading on the Nasdaq. Each unit consists of one share of common stock and a five-year warrant to purchase another share of common stock at $6.125.Aug 28, 2023 · A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit. We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ...Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over the
SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells.. The …Dec 1, 2023 · Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.
15 Jan 2021 ... That is the question for those investing in Bionano Genomics (NASDAQ: BNGO). ... The news comes on top of advances in coronavirus and in the ...SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells.. The …At Bionano, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, ...Investor Resources Email Alerts RSS Feeds Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress Sold 6,176 nanochannel array …Jan 10, 2023 · SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations August 04, 2023 at 12:01 pm EDT. SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.11 Jul 2023 ... BNGO stock is receiving lots of attention from retail investors, some who claim Bionano Genomics stock ... BREAKING NEWS - Bionano CFO Reveals Why ...Bionano Genomics (NASDAQ:BNGO) has effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10, effective after the market close on August 4, 2023.The Company ...Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
In 2022, BNGO's revenue was $27.80 million, an increase of 54.62% compared to the previous year's $17.98 million. Losses were -$132.60 million, 83.1% more than in 2021. According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $46.67, which is an increase of 2,853.80% from the latest …
BNGO: Get the latest Bionano Genomics stock price and detailed information including BNGO news, historical charts and realtime prices. Indices Commodities Currencies Stocks
Nov 3, 2022 · SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022. Aug 9, 2023 · Nov 3, 2022 at 4:30 PM EDT. Sep 12, 2022 at 7:00 AM EDT. 2022 Maxim Virtual Growth Conference. Mar 15, 2022 at 8:40 AM EDT. Please click HERE to join. Mar 9, 2022 at 2:10 PM EST. 42nd Annual Cowen Healthcare Conference. Please click HERE to join. Mar 1, 2022 at 4:30 PM EST. Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano …SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) for research, development, and manufacturing applications in stem ...For full-year 2023, Bionano reiterated its revenue guidance of $35.0 million to $38.0 million. The company’s Q2 revenues are expected to be in the range of $7.8 million to $8.3 million. In early morning trading on the Nasdaq, Bionano's shares were up about 7 percent at $.79.Oct 26, 2023 · For the last reported quarter, it was expected that Bionano Genomics, Inc. Would post a loss of $0.90 per share when it actually produced a loss of $1.24, delivering a surprise of -37.78%. News Release Details « Back. Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies. Feb 22, 2023 | PDF Version. ... About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers …For full-year 2023, Bionano reiterated its revenue guidance of $35.0 million to $38.0 million. The company’s Q2 revenues are expected to be in the range of $7.8 million to $8.3 million. In early morning trading on the Nasdaq, Bionano's shares were up about 7 percent at $.79.Let’s get ready to reconnect in Torino, Italy – stop by our booth #54! We’re on a mission to change the way the world sees the genome with genome mapping systems, nucleic acid purification solutions, analysis software, and clinical testing services. Come explore the genomic variation continuum, from SNVs to whole chromosomes, through our ... SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD).
Bionano also sold 3,204 nanochannel array flow cells during the quarter, representing 29 percent growth over the same quarter of 2020. Increased sales of flow cells "indicate more utilization in the field, which in turn leads to more data, more publications, more presentations, and, we believe, more demand for optical genome mapping," …SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …A high-level overview of Bionano Genomics, Inc. (BNGO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.News Release Details « Back. Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress. Aug 04, 2022 | PDF …Instagram:https://instagram. fdoordash stocknvda upgradehealth insurance providers pennsylvaniaday trading with charles schwab Mapping the Human Genome - Mapping the human genome is explained in this section. Learn about mapping the human genome. Advertisement If you think of the human body as big, complicated, encrypted code, then the scientists mapping the human... how to sell a stock on robinhoodufp technologies inc BABA. 78.34. +0.96%. 22.22M. Markets. View today's Bionano Genomics Inc stock price and latest BNGO news and analysis. Create real-time notifications to follow any changes in the live stock price.Bionano Genomics, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.75. Operator: Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. free options paper trading simulator SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.The study authors conducted a comprehensive analysis of samples from …Aug 28, 2023 · A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit.